Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biogen Backs Down From M&A

This article was originally published in Scrip

Executive Summary

Biogen Inc. wouldn't acknowledge rumors that it plans to sell its hemophilia business, but CEO George Scangos told analysts during a first quarter earnings call that the big biotech will be focusing on "cost control" and keeping its head down.


Related Content

Biogen Backs Out Of Hemophilia, But Who Benefits?